FDA granted approval Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for Soliris

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has been granted approval by the Food and Drug Administration for Soliris. Soliris (eculizumab) is an injection for intravenous use for the treatment of neuromyelitis optica spectrum disorder in adult patients who are anti-aquaporin-4 antibody positive.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), a Healthcare sector firm, traded 1.01 Million shares in last trading session with closing price of $126.11 per share. Company gross margin stands at 91.50% whereas its return on investment (ROI) is 0.40%. Stock value has moved between $92.73 – 141.7 in last one year. Analyst’s mean target price for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is $161.58 while analysts mean recommendation is 1.90. ALXN EPS growth this year is -95.70%. 

On last trading day, Annaly Capital Management, Inc. (NYSE:NLY) shares closed at $9.10 per share. NLY market capitalization is 13236.86 with beta of 0.46. Analyst’s mean target price for Annaly Capital Management, Inc. (NYSE:NLY) is $10.10 whereas analysts mean recommendation is 2.30. Its weekly performance is -0.44% while year to date (YTD) performance is -7.33%. 

In last session United States Steel Corporation (NYSE:X) traded 7.74 Million shares and was closed at $15.11. Analyst’s mean target price for X is $17.38 while analysts mean recommendation is 3.00. Company is -61.15% away from its 52 week high and is moving 29.48% ahead of its 52 week low. X Gross Margin is 12.80% and its return on assets is 10.80%. United States Steel Corporation (NYSE:X) quarterly performance is -22.03% while its price to sale ratio is 0.18. 

Rent-A-Center, Inc. (NASDAQ:RCII), a Services sector firm, traded 644344 shares on last trading day with closing price of $26.02 per share. Company gross margin stands at 63.00% whereas its return on investment (ROI) is 6.10%. Stock value has moved between $11.99 – 26.82 in last one year. Analyst’s mean target price for Rent-A-Center, Inc. (NASDAQ:RCII) is $26.00 while analysts mean recommendation is 2.90. RCII EPS growth this year is 112.00%. 

Leave a Reply